Market capitalization | $17.25b |
Enterprise Value | $17.57b |
P/E (TTM) P/E ratio | 22.89 |
EV/FCF (TTM) EV/FCF | 15.21 |
EV/Sales (TTM) EV/Sales | 4.36 |
P/S ratio (TTM) P/S ratio | 4.28 |
P/B ratio (TTM) P/B ratio | 3.43 |
Revenue growth (TTM) Revenue growth | 0.00% |
Revenue (TTM) Revenue | $4.03b |
As a Free StocksGuide user, you can view scores for all 6,879 stocks worldwide.
21 Analysts have issued a Hologic forecast:
21 Analysts have issued a Hologic forecast:
Sep '24 |
+/-
%
|
||
Revenue | 4,030 4,030 |
0%
0%
|
|
Gross Profit | 2,238 2,238 |
1%
1%
|
|
EBITDA | 1,279 1,279 |
1%
1%
|
EBIT (Operating Income) EBIT | 970 970 |
3%
3%
|
Net Profit | 790 790 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a broad portfolio of breast imaging and related products and accessories, including digital mammography systems, computer-aided detection, for mammography and minimally invasive breast biopsy devices, breast biopsy site markers, and breast biopsy guidance systems. The Diagnostics segment comprises Aptima family of Assays, target capture/nucleic acid extraction techonolgy, transcription-mediated amplification technology, hybridization protection assay and dual kinetic assat technologies, instrumentation, and Invader Chemistry Platform. The Medical Aesthetics segment offers SculpSure; PicoSure, MedLite, and RevLite; and MonaLisa Touch. The GYN Surgical segment encompasses the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment covers the discovery and horizon X-ray bone densitometry system, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in 1986 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Stephen MacMillan |
Employees | 7,063 |
Founded | 1985 |
Website | www.hologic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.